OTCMKTS:GNMSF - Genmab A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$170.30 -1.22 (-0.71 %)
(As of 05/20/2019 06:40 AM ET)
Previous Close$171.5250
Today's Range$170.30 - $170.30
52-Week Range$119.10 - $204.50
Volume3 shs
Average Volume340 shs
Market Capitalization$10.44 billion
P/E Ratio53.05
Dividend YieldN/A
Beta0.1
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNMSF
CUSIPN/A
CIKN/A
Phone45-7020-2728

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$359.31 million
Cash Flow$2.7397 per share
Book Value$15.57 per share

Profitability

Miscellaneous

Employees377
Market Cap$10.44 billion
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable

Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions

What is Genmab A/S's stock symbol?

Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) announced its earnings results on Wednesday, November, 5th. The company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.45 by $0.02. The business earned $45.65 million during the quarter, compared to analyst estimates of $53.94 million. View Genmab A/S's Earnings History.

When is Genmab A/S's next earnings date?

Genmab A/S is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Genmab A/S.

What is the consensus analysts' recommendation for Genmab A/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genmab A/S.

Has Genmab A/S been receiving favorable news coverage?

News stories about GNMSF stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Genmab A/S earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Genmab A/S's key competitors?

What other stocks do shareholders of Genmab A/S own?

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the folowing people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, CEO & Pres (Age 58)
  • Mr. David A. Eatwell, Exec. VP & CFO (Age 58)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61)
  • Ms. Jane Juel, Sr. Director of Operations & Resource Management
  • Mr. Peter Ros, Sr. Director of Fin. & Accounting

How do I buy shares of Genmab A/S?

Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genmab A/S's stock price today?

One share of GNMSF stock can currently be purchased for approximately $170.30.

How big of a company is Genmab A/S?

Genmab A/S has a market capitalization of $10.44 billion and generates $359.31 million in revenue each year. Genmab A/S employs 377 workers across the globe.

What is Genmab A/S's official website?

The official website for Genmab A/S is http://www.genmab.com.

How can I contact Genmab A/S?

Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]


MarketBeat Community Rating for Genmab A/S (OTCMKTS GNMSF)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  321
MarketBeat's community ratings are surveys of what our community members think about Genmab A/S and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel